Thursday, 25 Apr 2019

You are here

RheumNow Podcast – TNFs and the Inflammasome (1.25.19)

Dr Jack Cush reviews the news from the past week at RheumNow.com.

  1. Meta-analysis of 4719 elderly RA/IBD/PSO pts on biologics vs 13,305 younger vs 3961 older patients (no biologics) shows biologic use in elderly to be assoc w/ an increased risk of infections (3.6 fold increase in risk) but no increase in cancer or death https://t.co/pWtMMo2KQ1
  2. Using FMF-KI knockout mice (high TNF levels) researchers find TNF signaling drives pyrin & inflammasome activation; TNF is a critical modulator of pyrin of pyrin-inflammasomopathies like FMF. This is why TNF inhib sometimes work in inflammasomopathies. https://t.co/0EvuTI57tn
  3. Systematic review of literature and 478 RA patients (mostly female; age 53-64 yrs) shows 73 to 97% of patients being unaware of an increased risk of developing Cardiovascular Disease in relation to their RA, https://t.co/aNM3wI2KBo
  4. JAMA study shows that when drug companies increased their opioid marketing budgets by just $5.29 per 1,000 population, the number of MD opioid prescriptions went up 82% and opioid deaths increased 9%. https://t.co/4FAr53gH17 
  5. Using the 1998-2014 U.S. National Inpatient Sample- gout was associated with 9-20% higher healthcare utilization and 6% higher hazard of transfusion after primary hip replacement surgery. https://buff.ly/2U8wvwu
  6. Does Seropositivity Change with Therapy?
  7. Smoking Doesn't Influence Rituximab Responses in Rheumatoid Arthritis

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Ustekinumab Effective in Behcet's Disease

A small prospective study has shown that ustekinumab is safe and effective in Behçet's disease (BD) with recurrent oral ulcers (OU).

Polypharmacy Blunts Responses and Ups the Safety Risks

A study from the British Society for Rheumatology Biologics Register (BSRBR-RA) demonstrates that polypharmacy is a predictor of lower treatment responses and more serious adverse events (SAEs) in rheumatoid arthritis (RA) patients.

RheumNowLive On Demand: Development & Use of JAK Inhibitors - Dr. John O'Shea

A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.

For RA With COPD, Abatacept is Safe

Patients with rheumatoid arthritis (RA) who also had chronic obstructive pulmonary disease (COPD) had no increased risk of serious respiratory complications when treated with abatacept (Orencia), a large claims-based analysis found.

Ups and Downs with Abatacept

Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.